Key Takeaways:
- BHC reported Q2 2026 revenue and EPS results
- Figures compared against Wall Street consensus estimates
- Year-over-year comparisons show quarterly performance
Back
Bausch Health reports Q2 earnings as pharma sector faces pricing pressure
Bausch Health reported Q2 2026 revenue and earnings that compared against Wall Street estimates for the quarter ended June 30.
The company's results included revenue and EPS figures measured against consensus expectations and the prior-year period, according to the earnings release. The report covers the three months through June, a period when BHC continued advancing its debt reduction strategy.
BHC's performance comes as the pharmaceutical sector contends with pricing headwinds and patent expirations on legacy products. The company, which separated its Bausch + Lomb eye health unit into a standalone publicly traded entity, maintains a portfolio spanning gastroenterology, dermatology, and neurology.
The earnings report provides a snapshot of BHC's financial health amid its restructuring. Investors will watch the earnings call for management's updated 2026 outlook, debt reduction targets, and commentary on pipeline milestones.
This article is for informational purposes only and does not constitute investment advice.
[1] Bausch (BHC) Reports Q2 Earnings: What Key Metrics Have to Say[2] GE HealthCare targets 3% to 4% organic sales growth and $4.80 to $5 adjusted EPS in 2026 while reviewing Patient Care Solutions options[3] BHC Bausch Health Companies Inc.[4] Boston Scientific expects 2026 organic revenue growth of 5%-6% and outlines $500M run-rate savings exiting 2029[5] Takeda Pharmaceutical Company Limited (TAK)
